The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
In the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Flagged first, then by citations
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
Items 301–400 of 1,000
Muscoli, S., Barillà, F., Tajmir, R., Meloni, M., Della‐Morte, D., Bellia, A., Daniele, N. D., Lauro, D., & Andreadi, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081730 · Cited by 39
Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada
Carney, G., Kim, J. D., O’Sullivan, C., Thompson, W., Bassett, K. L., Levin, J., & Dormuth, C. R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002995 · Cited by 40
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Karagiannis, T., Kakotrichi, P., Michailidis, T., Liakos, A., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14555 · Cited by 39
The year in cardiovascular medicine 2021: heart failure and cardiomyopathies
Bauersachs, J. K., de Boer, R. A., Lindenfeld, J. M., & Bozkurt, B. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab887 · Cited by 39
Oikonomou, E. K., Suchard, M. A., McGuire, D. K., & Khera, R. (2022) · Diabetes Care · doi:10.2337/dc21-1765 · Cited by 39
Self-citationMonzo, L., Ferrari, I., Cicogna, F., Tota, C., Cice, G., Girerd, N., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad055 · Cited by 38
Jaiswal, A., Jaiswal, V., Ang, S. P., Hanif, M., Vadhera, A., Agrawal, V., Kumar, T., Nair, A. M., Borra, V., Garimella, V., et al. (2023) · Medicine · doi:10.1097/md.0000000000034693 · Cited by 41
Verma, A., Yadav, D. K., Natesan, S., Gupta, M., Yadav, B. C., & Mishra, Y. K. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.110713 · Cited by 39
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 39
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Gaba, P., Bhatt, D. L., Giugliano, R. P., Steg, P. G., Miller, M. J., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.009 · Cited by 38
Self-citationSodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Tharmaraja, T., Ho, J. S. Y., Sia, C., Lim, N.-A., Chong, Y. F. V., Lim, A. Y. L., Rathakrishnan, R., Yeo, L. L. L., Sharma, V. K., & Tan, B. Y. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221086996 · Cited by 38
Pitt, B., Bhatt, D. L., & Metra, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac417 · Cited by 38
Self-citationTsukamoto, S., Morita, R., Yamada, T., Urate, S., Azushima, K., Uneda, K., Kobayashi, R., Kanaoka, T., Wakui, H., & Tamura, K. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110161 · Cited by 38
Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14805 · Cited by 37
Self-citationDocherty, K. F., Bayés‐Genís, A., Butler, J., Coats, A. J. S., Drazner, M. H., Joyce, E., & Lam, C. S. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac113 · Cited by 40
Updates on New Therapies for Patients with CKD
Tarun, T., Ghanta, S. N., Ong, V., Kore, R. A., Menon, L., Kovesdy, C. P., Mehta, J. L., & Jain, N. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.006 · Cited by 43
Enhanced Decongestive Therapy in Patients With Acute Heart Failure
Cotter, G., Davison, B. A., & Chioncel, O. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.029 · Cited by 37
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., Inzucchi, S. E., Lópes, R. D., McGuire, D. K., Lewis, J. B., Riddle, M. C., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00362-0 · Cited by 38
Self-citationHundertmark, M., Agbaje, O. F., Coleman, R. L., George, J. T., Grempler, R., Holman, R. R., Lamlum, H., Lee, J., Milton, J. E., Niessen, H. G., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13406 · Cited by 37
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01295-6 · Cited by 37
Ueda, T., Kasama, S., Yamamoto, M., Nakano, T., Ueshima, K., Morikawa, Y., Kawata, H., Yoshihisa, A., Nakayama, M., Komatsu, S., et al. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0030 · Cited by 38
Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.12.005 · Cited by 38
Rao, S. D. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01989-z · Cited by 38
Mark, P. B., Mangion, K., Rankin, A. J., Rutherford, E., Lang, N. N., Petrie, M. C., Stoumpos, S., & Patel, R. K. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac146 · Cited by 40
Connelly, K. A., Mazer, C. D., Puar, P., Teoh, H., Wang, C., Mason, T., Akhavein, F., Chang, C., Liu, M., Yang, N., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062769 · Cited by 38
Self-citationSotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD
Sridhar, V. S., Bhatt, D. L., Odutayo, A., Szarek, M. J., Davies, M. J., Banks, P. L., Pitt, B., Steg, P. G., & Cherney, D. Z. I. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000414 · Cited by 36
Self-citationAdvances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 38
Lund, L. H., James, S. K., DeVore, A. D., Anstrom, K. J., Fudim, M., Aaronson, K. D., Dahlström, U., Desvigne-Nickens, P. M., Fleg, J. L., Yang, S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3453 · Cited by 36
Self-citationThe year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1061 · Cited by 36
Zheng, C., Lin, M., Chen, Y., Xu, H., Yan, L., & Dai, H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01272-z · Cited by 38
Dixit, N. M., Shah, S. P., Ziaeian, B., Fonarow, G. C., & Hsu, J. J. (2021) · US Cardiology Review · doi:10.15420/usc.2020.29 · Cited by 36
Täger, T., Frankenstein, L., Atar, D., Agewall, S., Frey, N., Grundtvig, M., Clark, A. L., Cleland, J. G. F., & Fröhlich, H. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01913-z · Cited by 38
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Vecchio, L. D., Beretta, A., Jovane, C., Peiti, S., & Genovesi, S. (2021) · Drugs · doi:10.1007/s40265-021-01573-3 · Cited by 37
Cox, Z. L., Nandkeolyar, S., Johnson, A. J., Lindenfeld, J. M., & Rali, A. S. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.08 · Cited by 36
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
Karakasis, P., Pamporis, K., Stachteas, P., Patoulias, D., Bougioukas, K. I., & Fragakis, N. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10324-3 · Cited by 35
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 36
Ferté, L., Marino, A., Battault, S., Bultot, L., Steenbergen, A. V., Bol, A., Cumps, J., Ginion, A., Koepsell, H., Dumoutier, L., et al. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00736.2019 · Cited by 35
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35
Pabel, S., Hamdani, N., Singh, J. S., & Sossalla, S. T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752370 · Cited by 36
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 35
Khan, M. S., Solomon, N. C., DeVore, A. D., Sharma, A., Felker, G. M., Hernandez, A. F., Heidenreich, P. A., Matsouaka, R., Green, J. B., Butler, J., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.11.001 · Cited by 35
Teo, Y. N., Ting, A. Z. H., Teo, Y. H., Chong, E. Y., Tan, J. T. A., Syn, N. L. X., Chia, A. Z. Q., Ong, H. T., Cheong, A. J. Y., Li, T. Y., et al. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00528-7 · Cited by 36
Sfairopoulos, D. G., Liu, T., Zhang, N., Tse, G., Bazoukis, G., Letsas, Κ. P., Goudis, C. A., Milionis, H. J., Vrettos, A., & Korantzopoulos, P. G. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10281-3 · Cited by 35
Kunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 35
Use of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 35
Escobar, C., Palacios, B., Varela, L. F., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08614-x · Cited by 34
Mentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 38
Tromp, J., Kosiborod, M., Angermann, C. E., Collins, S. P., Teerlink, J. R., Ponikowski, P. P., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3218 · Cited by 35
Self-citationKarakasis, P., Fragakis, N., Κούσκουρας, Κ., Karamitsos, T. D., Patoulias, D., & Rizzo, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.010 · Cited by 35
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 36
Spertus, J. A., Birmingham, M. C., Butler, J., Lingvay, I., Lanfear, D. E., Abbate, A., Kosiborod, M., Fawcett, C., Burton, P. B. J., Damaraju, C. V., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007767 · Cited by 35
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2021) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 35
Relationship of Dapagliflozin With Serum Sodium
Yeoh, S. E., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.01.019 · Cited by 37
Self-citationSodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Li, H., Tse, Y.-K., Chandramouli, C., Hon, N. W. L., Cheung, C., Lam, L.-Y., Wu, M., Huang, J.-Y., Yu, S.-Y., Leung, K. L. C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac558 · Cited by 34
Self-citationButler, J., Usman, M., Anstrom, K. J., Blaustein, R. O., Bonaca, M. P., Ezekowitz, J. A., Freitas, C., Lam, C. S. P., Lewis, E. F., Lindenfeld, J. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2720 · Cited by 34
Self-citationRao, V. N., Mentz, R. J., Coniglio, A. C., Kelsey, M. D., Fudim, M., Fonarow, G. C., Matsouaka, R., DeVore, A. D., & Caughey, M. C. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009353 · Cited by 34
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
Solomon, J., Festa, M. C., Chatzizisis, Y. S., Samanta, R., Suri, R. S., & Mavrakanas, T. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108330 · Cited by 34
Health‐related quality of life outcomes in PARAGON‐HF
Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2738 · Cited by 33
Lim, J., Choi, Y.-J., Kim, B. S., Rhee, T., Lee, H.-J., Han, K. D., Park, J., Na, J. O., Kim, Y.-J., Lee, H., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01911-7 · Cited by 33
Acute Heart Failure Is a Malignant Process: But We Can Induce Remission
Cotter, G., Davison, B. A., Lam, C. S. P., Metra, M., Ponikowski, P. P., Teerlink, J. R., & Mebazaa, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031745 · Cited by 33
Self-citationStandardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
Lala, A., HAMO, C. E., Bozkurt, B., Fiuzat, M., Blumer, V. L., Bukhoff, D., Butler, J., Costanzo, M. R., Felker, G. M., Filippatos, G. S., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.030 · Cited by 33
Self-citationSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow, D. A., Velazquez, E. J., Desai, A. S., DeVore, A. D., Lepage, S., Park, J., Sharma, K., Solomon, S. D., Starling, R. C., Ward, J. H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.027 · Cited by 37
Pană, M.-A., Boulmpou, A., İleri, Ç., Manzi, G., Golino, M., Ostojic, M., Galimzhanov, A. M., Busnatu, Ș., Mega, S., & Perone, F. (2025) · Medicina · doi:10.3390/medicina61020211 · Cited by 34
Sarak, B., Verma, S., Mazer, C. D., Teoh, H., Quan, A., Gilbert, R. E., Goodman, S. G., Bami, K., Coelho‐Filho, O. R., Ahooja, V., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01390-8 · Cited by 33
Self-citationTsampasian, V., Elghazaly, H., Chattopadhyay, R. K., Ali, O., Corballis, N. H., Chousou, P. A., Clark, A., Garg, P., & Vassiliou, V. S. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab189 · Cited by 33
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · Diabetes Care · doi:10.2337/dc21-2166 · Cited by 34
Deschaine, B., Verma, S., & Rayatzadeh, H. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.11 · Cited by 34
Self-citationZügner, E., Yang, H., Kotzbeck, P., Boulgaropoulos, B., Sourij, H., Hagvall, S., Elmore, C. S., ESTERLINE, R. L., Moosmang, S., Oscarsson, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147966 · Cited by 35
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
Panico, C., Bonora, B. M., Camera, A., Chilelli, N. C., Prato, G. D., Favacchio, G., Grancini, V., Resi, V., Rondinelli, M., Zarra, E., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01855-y · Cited by 33
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 33
Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis
Younes, A. M., Salem, M. A., Maraey, A. M., Nomigolzar, S., Sewell, K. B., Khalil, M., Elzanaty, A., Saeyeldin, A. A., & Dar, M. S. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.059 · Cited by 32
Evolving Diagnostic and Management Advances in Coronary Heart Disease
Ribeiro, M. D. O. L., Correia, V. M., de Oliveira, L. L. H., Soares, P. R., & Scudeler, T. L. (2023) · Life · doi:10.3390/life13040951 · Cited by 32
Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights
D’Amato, A., Prosperi, S., Severino, P., Myftari, V., Francia, A. L., Cestiè, C., Pierucci, N., Marek‐Iannucci, S., Mariani, M. V., Germanò, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031574 · Cited by 31
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 35
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
Staplin, N., Roddick, A., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Fletcher, R. A., Inzucchi, S. E., et al. (2025) · JAMA · doi:10.1001/jama.2025.20835 · Cited by 31
Self-citationPacker, M., Butler, J., Filippatos, G. S., Zannad, F. M., Ferreira, J. P., Zeller, C., Brueckmann, M., Jamal, W., Pocock, S., & Anker, S. D. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2065 · Cited by 31
Ameri, P., Bertero, E., Maack, C., Teerlink, J. R., Rosano, G. M. C., & Metra, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab033 · Cited by 31
Self-citationde la Espriella, R., Santas, E., Reiriz, I. Z., Górriz, J. L., Marcos, M. C., & Núñez, J. E. (2021) · Nefrología · doi:10.1016/j.nefro.2021.04.006 · Cited by 31
Li, C., Yu, J., Hockham, C., Perkovic, V., Neuen, B. L., Badve, S. V., Houston, L., Lee, V. Y., Barraclough, J., Fletcher, R. A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14772 · Cited by 31
Self-citationCanepa, M., Kapelios, C. J., Benson, L., Savarese, G., & Lund, L. H. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009462 · Cited by 32
Self-citationThe Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 30
Wang, Y., Gao, T., Meng, C., Li, S., Bi, L., Geng, Y., & Zhang, P. (2022) · European journal of medical research · doi:10.1186/s40001-022-00945-z · Cited by 31
Aziri, B., Begić, E., Јаnkovic, S., Mladenović, Z., Stanetić, B., Kovačević-Preradović, T., Iglica, A., & Mujaković, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14355 · Cited by 30
Lee, V. Y., Houston, L., Perkovic, A., Barraclough, J., Sweeting, A., Yu, J., Fletcher, R. A., & Arnott, C. G. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.022 · Cited by 31
Mahé, G., Aboyans, V., Cosson, E., Mohammedi, K., Sarlon-Bartoli, G., Lanéelle, D., Mirault, T., & Darmon, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02325-9 · Cited by 32
Laborante, R., Paglianiti, D. A., Bianchini, E., Galli, M., Borovac, J. A., Savarese, G., Patti, G., & D’Amario, D. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.01.014 · Cited by 30
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30153112 · Cited by 30
Verma, S., Anker, S. D., Butler, J., & Bhatt, D. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13148 · Cited by 30
Self-citationRecent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 35
Li, N., Zhou, G., Zheng, Y., Lv, D., Zhu, X., Wei, P., Zheng, M., Liu, S., Zhou, E., Sun, W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261986 · Cited by 30
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 30
Malhotra, A., Cole, K. V., Malik, A., Pépin, J., Kuniyoshi, F. H. S., Cistulli, P. A., Benjafield, A., Somers, V. K., Cistulli, P. A., Malhotra, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028732 · Cited by 32
Fu, E. L., Patorno, E., Everett, B. M., Vaduganathan, M., Solomon, S. D., Levin, R., Schneeweiß, S., & Desai, R. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad273 · Cited by 30
SGLT2 inhibitors in cardiovascular medicine
Varzideh, F., Kansakar, U., & Santulli, G. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab039 · Cited by 32
Bhatia, K., Jain, V., Gupta, K., Bansal, A., Fox, A., Qamar, A., Damman, K., & Vaduganathan, M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2135 · Cited by 30
Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Self-citationKidney Drug Transporters in Pharmacotherapy
Łapczuk-Romańska, J., Droździk, M., Oswald, S., & Droździk, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032856 · Cited by 29
Diabetes Mellitus in Acute Coronary Syndrome
Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 30
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
